141 related articles for article (PubMed ID: 27412968)
21. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.
Thang SP; Lung MS; Kong G; Hofman MS; Callahan J; Michael M; Hicks RJ
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):262-277. PubMed ID: 28894897
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
23. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
24. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
25. Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index.
Lee HE; Mounajjed T; Erickson LA; Wu TT
Endocr Pathol; 2016 Sep; 27(3):259-67. PubMed ID: 27306997
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors.
Hasegawa T; Yamao K; Hijioka S; Bhatia V; Mizuno N; Hara K; Imaoka H; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Kinoshita T; Kohsaki T; Nishimori I; Iwasaki S; Saibara T; Hosoda W; Yatabe Y
Endoscopy; 2014 Jan; 46(1):32-8. PubMed ID: 24218309
[TBL] [Abstract][Full Text] [Related]
27. How reliable is the Ki-67 cytological index in grading pancreatic neuroendocrine tumors? A meta-analysis.
Li J; Lin JP; Shi LH; Wang WJ; Li AQ; Si JM; Chen SJ
J Dig Dis; 2016 Feb; 17(2):95-103. PubMed ID: 26713749
[TBL] [Abstract][Full Text] [Related]
28. Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms.
Ono H; Kudo A; Akahoshi K; Ogura T; Ogawa K; Ban D; Tanaka S; Tanabe M
J Cancer Res Clin Oncol; 2020 Mar; 146(3):793-799. PubMed ID: 31844980
[TBL] [Abstract][Full Text] [Related]
29. Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours.
Ricci C; Casadei R; Taffurelli G; Campana D; Ambrosini V; Pagano N; Santini D; De Giorgio R; Ingaldi C; Tomassetti P; Zani E; Minni F
Pancreatology; 2016; 16(3):403-10. PubMed ID: 26924664
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.
Turner NC; Strauss SJ; Sarker D; Gillmore R; Kirkwood A; Hackshaw A; Papadopoulou A; Bell J; Kayani I; Toumpanakis C; Grillo F; Mayer A; Hochhauser D; Begent RH; Caplin ME; Meyer T
Br J Cancer; 2010 Mar; 102(7):1106-12. PubMed ID: 20234360
[TBL] [Abstract][Full Text] [Related]
31. Ki-67 is a reliable pathological grading marker for neuroendocrine tumors.
Nadler A; Cukier M; Rowsell C; Kamali S; Feinberg Y; Singh S; Law CH
Virchows Arch; 2013 May; 462(5):501-5. PubMed ID: 23588555
[TBL] [Abstract][Full Text] [Related]
32. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
[TBL] [Abstract][Full Text] [Related]
33. High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Improved Prognostic Stratification With the New World Health Organization 2019 Classification: A Validation Study From a Single-Institution Retrospective Analysis.
Hayes AR; Furnace M; Shah R; Rundell C; Muller G; Dehbi HM; Luong TV; Toumpanakis C; Caplin ME; Krell D; Thirlwell C; Mandair D
Pancreas; 2021 Apr; 50(4):516-523. PubMed ID: 33939663
[TBL] [Abstract][Full Text] [Related]
34. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
35. Correlation of Ki-67 indices from biopsy and resection specimens of neuroendocrine tumours.
Barnes J; Johnson SJ; French JJ
Ann R Coll Surg Engl; 2017 Mar; 99(3):193-197. PubMed ID: 27490982
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index.
Weynand B; Borbath I; Bernard V; Sempoux C; Gigot JF; Hubert C; Lannoy V; Deprez PH; Jouret-Mourin A
Cytopathology; 2014 Dec; 25(6):389-95. PubMed ID: 24750272
[TBL] [Abstract][Full Text] [Related]
37. Toxicities, safeties and clinical response of dacarbazine-based chemotherapy on neuroendocrine tumors in Taiwan population.
Chiu HY; Lin LY; Chou WC; Fang WL; Shyr YM; Yeh YC; Mu-Hsin Chang P; Chen MH; Hung YP; Chao Y; Chien SH; Chen MH
J Chin Med Assoc; 2018 May; 81(5):423-428. PubMed ID: 29287706
[TBL] [Abstract][Full Text] [Related]
38. Ki-67 is a powerful tool for grading neuroendocrine tumors among Egyptian patients: a 10-year experience.
Salama A; Badawy O; Mokhtar N
J Cancer Res Clin Oncol; 2014 Apr; 140(4):653-61. PubMed ID: 24515911
[TBL] [Abstract][Full Text] [Related]
39. Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3.
Ali AS; Perren A; Lindskog C; Welin S; Sorbye H; Grönberg M; Janson ET
Sci Rep; 2020 Jun; 10(1):10639. PubMed ID: 32606315
[TBL] [Abstract][Full Text] [Related]
40. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
